Has Christopher Dakhil, MD received payments from drug or device companies?

Yes. Drug and device makers reported $113,557 in general payments to Christopher Dakhil, MD across 1,127 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Dakhil, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Dakhil, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Dakhil, MD

Hematology & Oncology · Wichita, KSNPI 1972721348

Payments from drug & device makers

$113,557in general payments, 2019–2025

Across 1,127 payments — averaging $100.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$57K
Daiichi Sankyo Inc.$30K
AstraZeneca$4K
Novartis$3K
F. Hoffmann-la Roche AG$2K
Bristol Myers Squibb$1K
plus $16K from 54 others

$1,537in research payments, 2019–2025

Across 1 payment — averaging $1536.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	100	$56,803
Daiichi Sankyo Inc.	52	$30,452
AstraZeneca(2 entities)	51	$4,196
Novartis	104	$2,542
F. Hoffmann-la Roche AG	2	$1,722
Bristol Myers Squibb	66	$1,244
E.r. Squibb & Sons, L.L.C.	81	$1,137
Rigel Pharmaceuticals, Inc.	9	$969
Merck	56	$849
Karyopharm Therapeutics Inc.	7	$848
Genentech USA, Inc.	36	$832
Geron Corporation	4	$813
Johnson & Johnson	27	$675
AbbVie	40	$648
Seagen Inc.	37	$605
Gilead(2 entities)	42	$560
Sanofi	29	$515
Amgen	34	$506
Verity Pharmaceuticals Inc.	1	$500
EMD Serono, Inc.	36	$450
Array Biopharma Inc	22	$413
Astellas Pharma US Inc	21	$354
Athenex Pharmaceutical Division, LLC	2	$350
Eisai Inc.	13	$333
Takeda Pharmaceuticals U.S.A., Inc.	13	$323
Pharmacyclics LLC, An Abbvie Company	16	$288
Bayer	12	$277
GSK	15	$244
Incyte Corporation	7	$212
Puma Biotechnology, Inc.	5	$182
Regeneron Healthcare Solutions, Inc.	9	$171
Taiho Oncology, Inc.	4	$163
Sun Pharmaceutical Industries Inc.	10	$161
Dova Pharmaceuticals	4	$157
Epizyme, Inc.	10	$156
Tesaro, Inc.	3	$148
Sobi, Inc	5	$144
Verastem, Inc.	2	$137
Exelixis Inc.	6	$137
Acrotech Biopharma Inc.	8	$136
Beigene USA, Inc.	9	$126
AVEO Pharmaceuticals, Inc.	7	$119
Lilly USA, LLC	6	$112
Tersera Therapeutics LLC	5	$96
Jazz Pharmaceuticals Inc.	5	$96
Kyowa Kirin, Inc.	5	$87
Genmab U.S., Inc.	5	$80
Clovis Oncology, Inc.	5	$73
US Oncology Corporate, Inc.	1	$70
Ipsen Biopharmaceuticals, Inc	4	$68
Servier Pharmaceuticals LLC	4	$67
Immunocore Limited	3	$61
Boehringer Ingelheim	3	$59
Mylan Institutional Inc.	4	$57
Morphosys, US Inc.	1	$52
Pharmaessentia USA Corporation	3	$50
Stemline Therapeutics Inc.	3	$47
Deciphera Pharmaceuticals Inc.	3	$46
Blue Earth Diagnostics	3	$46
Blueprint Medicines Corporation	3	$41

How this compares

$113,557 in reported general payments places this provider in the 75th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas →

Medicare billing

Part B allowed, 2024

$11,507,666

Medicare patients

1,413

Services billed

465,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Wichita

Shaker DakhilWichita$11.2M
Bassam MattarWichita$1.9M
Quoc TruongWichita$539K
Phu TruongWichita$73K
Pavan ReddyWichita$69K
Nassim NabboutWichita$29K
Jeremy DeutschWichita$28K
Dennis MooreWichita$26K
Seth PageWichita$19K
Priyanka SharmaWestwood$18.5M

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →